177Lu-FAPI Therapy in a Patient With End-Stage Metastatic Pancreatic Adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000004021
Abstract: ABSTRACT A 52-year-old woman with metastatic pancreatic adenocarcinoma underwent imaging with 18F-FDG PET/CT and 68Ga-FAPI-46 PET/CT, which demonstrated malignancy recurrence in the surgical bed with multiple metastatic lesions, more extensive on 68Ga-FAPI-46 PET/CT. The patient… read more here.
Keywords: metastatic pancreatic; therapy; pancreatic adenocarcinoma; 68ga fapi ... See more keywords
FAP-Targeted Radionuclide Therapy of Advanced Radioiodine-Refractory Differentiated Thyroid Cancer With Multiple Cycles of 177Lu-FAPI-46.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000004260
Abstract: ABSTRACT Many recent studies began to explore the therapeutic potential of FAP-targeted radionuclide therapy for refractory cancers. In this case, we presented the experience of multiple cycles of 177Lu-FAPI-46 radionuclide therapy in a 34-year-old man… read more here.
Keywords: fap targeted; refractory; radionuclide therapy; 177lu fapi ... See more keywords
Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics
Sign Up to like & getrecommendations! Published in 2022 at "Theranostics"
DOI: 10.7150/thno.68182
Abstract: Rationale: Fibroblast activation protein (FAP) targeted molecular imaging radiotracers have shown promising preclinical and clinical results in tumor diagnosis. However, rapid clearance and inadequate tumor retention of these molecules have hindered them for further clinical… read more here.
Keywords: fapi; activation protein; fibroblast activation; 177lu fapi ... See more keywords